Progyny opened higher at $28.66, compared with its previous close of $28.40. In the last trading session, the stock traded between $28.30 and $28.88. It showed an upward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Progyny is now worth
$ 47.01
resulting in a loss of
$ 52.99 (52.99%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
77.78%
Hold
22.22%
Sell
0%
Markets Today
Today's Change
+$0.48 (+1.69%)
Day High
$28.88
Day Low
$28.30
Day Open
$28.66
Prev Close
$28.40
Volume
2,18,980
1W Return
-0.82%
1M Return
16.47%
3M Return
-7.85%
6M Return
56.79%
1Y Return
51.28%
Fundamentals
Market Cap ($ Mn)
2,216
PE Ratio
28.26
PB Ratio
4.44
PEG Ratio
9.13
ROE
11.80%
ROCE
16.42%
EPS (TTM)
$0.37
Investment Returns
1 Week
-0.82%
1 Month
16.47%
3 Months
-7.85%
6 Months
56.79%
9 Months
19.73%
Financials
Quarterly
All values in $ Mn
324.0
Mar 25
332.9
Jun 25
313.3
Sep 25
318.4
Dec 25
328.5
Mar 26
350.5
Jun 26
Updates
21Oct
Progyny Q3FY26 Results: Earnings call set for November 4
Progyny to report Q3FY26 results on November 4, 2026. Conference call scheduled for 4:45 pm ET. Audio replay available until November 11, 2026. Results cover period ended September 30, 2026.
9 days ago
7Oct
Progyny selling season paces to record with 1.2 million new covered lives
Progyny expects 1.2 million new covered lives from launches in the first half of 2027. Selling season pacing to potential record level for new lives added. Growth driven by employers seeking to mitigate broader medical cost inflation. Solutions focus on lowering risks of high-cost complications like multiple births.
23 days ago
3Sep
Progyny CFO to present at Wells Fargo healthcare conference
Progyny CFO Mark Livingston to present at Wells Fargo conference. Session scheduled for September 8, 2026, at 11:00 am ET. Live audiocasts and replays available on investor relations site.
1mo ago
20Aug
Wells Fargo initiates Progyny coverage with Overweight rating, $37 target
Wells Fargo initiates coverage on Progyny with an Overweight rating. Analyst Stan Berenshteyn sets a price target of $37. The move marks the first public institutional stance on the stock. Progyny trades under the ticker PGNY on the NASDAQ exchange.
2mo ago
7Aug
Progyny CEO Pete Anevski to present at Canaccord Genuity conference
Progyny Inc. confirmed CEO Pete Anevski will speak at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The session will be held in Boston at 3:30 p.m. ET. Investors can access live audiocasts and replays via the company's investor relations website.
2mo ago
28Jul
Barclays downgrades Progyny to Equal-Weight, raises price target to $34
Barclays analyst Peter Warendorf downgraded Progyny (NASDAQ: PGNY) from Overweight to Equal-Weight. Concurrently, the firm raised its price target from $27 to $34, indicating a higher valuation expectation despite the neutralized investment recommendation.
